{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T04:09:59Z","timestamp":1770437399578,"version":"3.49.0"},"reference-count":10,"publisher":"SMC Media","issue":"2","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Dermatomyositis (DM) is an autoimmune inflammatory myopathy that may rarely be drug induced. Statin-induced dermatomyositis (DIDM) is uncommon, with only few atorvastatin-related cases described in the literature. We present a case of a 62-year-old Hispanic woman who developed progressive proximal muscle weakness, myalgias, and joint discomfort shortly after initiating atorvastatin therapy. Despite discontinuation of the statin, her symptoms persisted and were accompanied by new cutaneous lesions. Laboratory evaluation revealed marked elevation of muscle enzymes, and subsequent skin biopsy revealed lymphocytic perivascular and perifollicular infiltrated with dermal mucin. Autoimmune serologies were negative, and malignancy screening was unremarkable. Treatment with systemic corticosteroids and mycophenolate mofetil resulted in gradual improvement. This report underscores the diagnostic challenges in differentiating statin-induced rhabdomyolysis from inflammatory myopathy, highlights the potential for rapid onset of dermatomyositis after statin exposure, and expands the limited literature on DIDM in Hispanic patients. By sharing this case, we aim to raise awareness among clinicians of this rare but clinically significant association, emphasizing the need for early recognition, histopathology, and malignancy screening to optimize outcomes.<\/jats:p>","DOI":"10.12890\/2026_006098","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:38:05Z","timestamp":1770136685000},"source":"Crossref","is-referenced-by-count":0,"title":["Dermatomyositis mimicking statin-induced myopathy in a 62-year-old woman"],"prefix":"10.12890","volume":"13","author":[{"given":"Itzamar","family":"Pastrana-Echevarria","sequence":"first","affiliation":[{"name":"Department of Graduate Medical Education, Centro M\u00e9dico Hospital Episcopal San Lucas, Ponce, Puerto Rico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merab","family":"Rivera-Serrano","sequence":"first","affiliation":[{"name":"Department of Physics and Chemistry, University of Puerto Rico, Ponce, Puerto Rico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina","family":"Cancel-Artau","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Puerto Rico School of Medicine, San Juan, Puerto Rico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Bury-Fiol","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Centro M\u00e9dico Hospital Episcopal San Lucas, Ponce, Puerto Rico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10397","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"10.12890\/2026_006098_ref1","doi-asserted-by":"crossref","unstructured":"Bi J, Xie H, Yang Y, Chen Q, Cui B, Xiao Z. Drug-induced dermatomyositis: a pharmacovigilance study of the FDA adverse event reporting system. Front Pharmacol 2025;16:1526836. doi: 10.3389\/fphar.2025.1526836","DOI":"10.3389\/fphar.2025.1526836"},{"key":"10.12890\/2026_006098_ref2","doi-asserted-by":"crossref","unstructured":"Bolender CM, Jimenez A, Clarke JT, Willson TM, Stevens VW, et al. Incidence of Dermatomyositis in a Nationwide Cohort Study of US Veterans. JAMA Dermatol 2022;158:1321-1323. doi: 10.1001\/jamadermatol.2022.3112","DOI":"10.1001\/jamadermatol.2022.3112"},{"key":"10.12890\/2026_006098_ref3","doi-asserted-by":"crossref","unstructured":"Waldman R, DeWane ME, Lu J. Dermatomyositis: Diagnosis and treatment. J Am Acad Dermatol 2020;82:283-296. doi: 10.1016\/j.jaad.2019.05.105","DOI":"10.1016\/j.jaad.2019.05.105"},{"key":"10.12890\/2026_006098_ref4","doi-asserted-by":"crossref","unstructured":"Yu K, Wang T, An D, Li X, Tang Z. Investigating the disparities among drug categories in drug-induced dermatomyositis: A systematic review. Semin Arthritis Rheum 2024;67:152478. doi: 10.1016\/j.semarthrit.2024.152478","DOI":"10.1016\/j.semarthrit.2024.152478"},{"key":"10.12890\/2026_006098_ref5","doi-asserted-by":"crossref","unstructured":"Chemello RML, Benvegn\u00fa AM, Dallazem LND, Chemello D. Aggressive and fatal statin-induced dermatomyositis: a case report. Oxf Med Case Reports 2017;2017:omx063. doi: 10.1093\/omcr\/omx063","DOI":"10.1093\/omcr\/omx063"},{"key":"10.12890\/2026_006098_ref6","doi-asserted-by":"crossref","unstructured":"Visconti MJ, Bashyam AM, Jorizzo JL. Statin-induced dermatomyositis for the practicing dermatologist: a review of the literature. Int J Dermatol 2020;59:383-387. doi: 10.1111\/ijd.14751","DOI":"10.1111\/ijd.14751"},{"key":"10.12890\/2026_006098_ref7","doi-asserted-by":"crossref","unstructured":"Metko D, Bednar DE, Alkhayal F, Pavlova V, Legault K, Abu-Hilal M. Characteristics of Patients With Adult-Onset Dermatomyositis at 2 Tertiary Care Centres in Ontario, Canada. J Cutan Med Surg 2025;29:124-130. doi: 10.1177\/12034754241301409","DOI":"10.1177\/12034754241301409"},{"key":"10.12890\/2026_006098_ref8","doi-asserted-by":"crossref","unstructured":"Wolstencroft PW, Rieger KE, Leatham HW, Fiorentino DF. Clinical factors associated with cutaneous histopathologic findings in dermatomyositis. J Cutan Pathol 2019;46:401-410. doi: 10.1111\/cup.13442","DOI":"10.1111\/cup.13442"},{"key":"10.12890\/2026_006098_ref9","doi-asserted-by":"crossref","unstructured":"de Andrade VP, De Souza FHC, Behrens Pinto GL, Shinjo SK. The relevance of anti-Jo-1 autoantibodies in patients with definite dermatomyositis. Adv Rheumatol 2021;61:12. doi: 10.1186\/s42358-021-00171-x","DOI":"10.1186\/s42358-021-00171-x"},{"key":"10.12890\/2026_006098_ref10","doi-asserted-by":"crossref","unstructured":"Oztas M, Ugurlu S, Aydin O. Atorvastatin-induced dermatomyositis. Rheumatol Int 2017;37:1217-1219. doi: 10.1007\/s00296-017-3658-9","DOI":"10.1007\/s00296-017-3658-9"}],"container-title":["European Journal of Case Reports in Internal Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/6098\/5092","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/6098\/5093","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/6098\/5093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T14:37:51Z","timestamp":1770388671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/view\/6098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":10,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.12890\/2026_006098","relation":{"has-manifestation":[{"id-type":"other","id":"1-163-6098-g5092","asserted-by":"subject"},{"id-type":"other","id":"1-163-6098-g5093","asserted-by":"subject"}],"is-part-of":[{"id-type":"other","id":"1-163","asserted-by":"subject"}]},"ISSN":["2284-2594"],"issn-type":[{"value":"2284-2594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]}}}